Yukari Manabe, MD

CRS:

JHU

Role:

Investigators

Position:

Investigator

Email:

ymanabe@jhmi.edu

As part of the Center for Global Health, Dr. Manabe is interested in rapid diagnostics suitable for the resource-limited settings particularly in sub-Saharan Africa (SSA). She began her career working on the basic science aspects of tuberculosis (TB) immunopathogenesis in comparative animal models of infection, particularly latency, reactivation, and immune reconstitution inflammatory syndrome (IRIS) in the rabbit model within the Johns Hopkins Center for Tuberculosis Research. In 2007, she was seconded to the Infectious Diseases Institute (IDI) at Makerere College of Health Sciences as the Associate Medical Laboratory Director of the College of American Pathologists certified Makerere University-Johns Hopkins University Clinical Core Lab to study antiretroviral associated TB and IRIS. She then became the Head of Research at the IDI in 2008 until 2012 where she built research capacity and infrastructure for training Ugandan investigators. Her research has focused on accuracy testing of various rapid, point-of-care diagnostics for HIV and related infectious diseases of clinical importance in SSA. She is also interested in studying the impact of various diagnostic interventions on disease detection and patient outcomes.

Dr. Yukari Manabe obtained her undergraduate degree from Yale University and her M.D. from Columbia University College of Physicians and Surgeons. After completing both her residency in Internal Medicine and fellowship in Infectious Diseases at Johns Hopkins Hospital, she joined the faculty in 1999.

  • NWCS 408, parent study A5274

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More